Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Alnylam Pharmaceuticals (NQ: ALNY )

253.07 -0.67 (-0.26%)
Streaming Delayed Price Updated: 1:00 PM EST, Nov 29, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Alnylam Pharmaceuticals

< Previous 1 2 3 4 5 6 Next >
Alnylam to Present Additional Data from the APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy at the Heart Failure Society of America Annual Scientific Meeting 2022
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam Announces Pricing of Offering of $900 Million Convertible Senior Notes
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam Announces Proposed Offering of $900 Million Convertible Senior Notes
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam Presents Positive Results from the APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam to Webcast Presentation at Morgan Stanley 20th Annual Global Healthcare Conference
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam Reports Positive Results from Phase 2 Study of Investigational Cemdisiran for the Treatment of IgA Nephropathy
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam Announces Appointment of Elliott Sigal, M.D., Ph.D., to Board of Directors
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam to Present Data from the APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy at the 18th International Symposium on Amyloidosis
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam Reports Positive Topline Results from APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam Ranks #1 on Fast Company’s Fourth Annual List of the 100 Best Workplaces for Innovators
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam Pharmaceuticals Reports Second Quarter 2022 Financial Results and Highlights Recent Period Activity
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam Uncovers Genetic Mutations in INHBE That Protect Against Abdominal Obesity
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam to Webcast Conference Call Discussing Second Quarter 2022 Financial Results
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam Announces FDA Approval of AMVUTTRA™ (vutrisiran), an RNAi Therapeutic for the Treatment of the Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis in Adults
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam Reports Positive Topline Results from Phase 2 Study of Investigational Cemdisiran for the Treatment of IgA Nephropathy
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam to Webcast Presentations at Upcoming June Investor Conferences
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam Announces Publication of Preclinical Results Based on Novel Conjugate Technology That Facilitates Delivery of Short Interfering RNA to the Central Nervous System and Other Extrahepatic Tissues
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam Presents New Results from the ILLUMINATE-C Phase 3 Study of Lumasiran in Patients with Advanced Primary Hyperoxaluria Type 1
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam Presents New 18-Month Results from Exploratory Cardiac Endpoints in HELIOS-A Phase 3 Study of Investigational Vutrisiran
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam to Webcast Presentations at Upcoming May Investor Conferences
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam Pharmaceuticals Reports First Quarter 2022 Financial Results and Highlights Recent Period Activity
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam to Webcast Conference Call Discussing First Quarter 2022 Financial Results
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam Announces Retirement of Steven Paul, M.D. from Board of Directors
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam Announces 3-Month Extension of Review Period for New Drug Application for Vutrisiran
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam to Webcast Presentation at Stifel 2022 CNS Days
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam Pharmaceuticals Files Patent Infringement Suits against Pfizer and Moderna
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam Issues 2021 Corporate Responsibility Report
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam Debuts New Documentary, Two of Me: Living with Porphyria, to Help Shorten Time to Diagnosis for Acute Hepatic Porphyria (AHP)
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights Recent Period Activity
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam to Webcast Presentation at 11th Annual SVB Leerink Global Healthcare Conference
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.